New hope for kids with pompe disease: expanded access to experimental therapy
NCT ID NCT04327973
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This expanded access program offers a new treatment combination (ATB200 and AT2221) to children with infantile-onset Pompe disease who are not eligible for other clinical trials and are declining on standard enzyme replacement therapy. The goal is to provide access to this experimental therapy for up to 18 years old. While not a cure, it may help control the disease and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATB200 (enzyme replacement therapy) co-administered with AT2221 (miglustat)
What this could lead to
If this treatment works, it could offer a new option for children with infantile-onset Pompe disease who are not doing well on standard therapy.
What could go wrong
This is an expanded access program, not a formal trial, so results are limited. The treatment may not work for everyone, and there are risks like infusion reactions or side effects from the drug combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POMPE DISEASE INFANTILE-ONSET are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
AVAILABLETaipei, 10002, Taiwan
-
UCSF Benioff Children's Hospital Oakland
AVAILABLEOakland, California, 94609, United States
-
UF Health Shands Hospital
AVAILABLEGainesville, Florida, 32610, United States
-
University Hospital of Padova
AVAILABLEPadova, Italy